GlassScriptPhysician profile
Marcus C Reeves
NPI 1457314007
$2,398.59
in general payments reported to CMS, 2019-2025
23 companies · $565 in 2025
The $565 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $250 · 2021: $291 · 2022: $448 · 2023: $255 · 2024: $293 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.84 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $415.97 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $362.31 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $358.49 | 2019-2023 | |
| Lilly USA, LLC | $319.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $181.76 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $177.12 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.33 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $55.30 | 2019-2022 | |
| Abbvie INC. | $54.61 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.56 | 2023-2025 | |
| Hologic Sales and Service, LLC | $39.10 | 2022 | |
| Dexcom, INC. | $33.84 | 2023-2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $28.43 | 2024 | Slynd |
| Glaxosmithkline, LLC. | $25.14 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $24.22 | 2024 | Amvuttra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.44 | 2023 | Keveyis |
| Teva Pharmaceuticals USA, INC. | $19.32 | 2020 | |
| Ascensia Diabetes Care US INC. | $17.27 | 2025 | |
| Allergan, INC. | $17.23 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $16.41 | 2024 | |
| Horizon Therapeutics Plc | $12.62 | 2021 | |
| Merck Sharp & Dohme LLC | $12.44 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.